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Background: The amino terminal region of Htt can be SUMO
modified and this modification appears relevant to HD
pathogenesis in vivo. Our goal is to establish the hierarchy of
SUMO modification in the amino terminal region and identify
key SUMO enzymes involved. Identification of the specific
enzymes that play a role in SUMOylation of Htt may provide
novel therapeutic targets for treatment of HD.
Methods/Techniques: To establish hierarchy, the three modifi-
able lysines (K6, K9, K15) present within Httex1 were mutated
singly or in combination, purified, and evaluated using an in
vitro SUMOylation assay, followed by mass spectrometry
analysis. To identify candidate Htt-SUMO enzymes, His
tagged proteins were purified under denaturing conditions and
analyzed using a quantitative western blotting technique. To
determine expression and distribution of the SUMO enzymes,
mRNA levels in R6/2 cortex and striata were analyzed using
qRT-PCR.
Results/Outcomes: Our results reveal site-specific modifica-
tions and establish a hierarchy of Lys 6 as the preferred
SUMO modified lysine followed by Lys 9. SUMO enzymes
evaluated for their ability to increase/decrease SUMO modifi-
cation of Htt revealed that a single PIAS enhances and two
SENPs reduce SUMOylation of Htt, suggesting these enzymes
may be relevant for Htt SUMOylation. Preliminary knock-
down data validates this possibility as do qRT-PCR results
indicating that these SUMO modification enzymes are highly
expressed in mouse brain. Experiments are ongoing to evaluate
the functional significance of Htt SUMOylation in HD and
extend analyses to longer forms of Htt.
Conclusions: Experimental results reveal selectivity for site-
specific SUMO modification within the amino terminal region
of Htt and specificity among SUMO modification enzymes.
Together with differential expression patterns in brain, these
SUMO enzymes are potential targets for treatment in HD.
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Background: Huntington disease (HD) cell lines, brains from
HD mice and post-mortem cerebral tissues and primary fibro-
blasts from HD patients show a reduction in mRNA levels of
key-cholesterogenic genes and in cholesterol biosynthesis activ-
ity. The underlying molecular mechanism entails hampered
activity of SREBP transcription factor in HD cells.
Methods/Techniques: Isotopic dilution Mass Spectrometry,
cellular, molecular and biochemical assays have been used to
measure different parameters related to cholesterol biosynthe-
sis and eﬄux in vivo and in vitro.
Results/Outcomes: We have measured the activity of the cho-
lesterol pathway in brain samples from a number of transgenic
mice and rats. Here we show that lathosterol levels are reduced
in brain samples from YAC46, YAC72 and YAC128 mice in a
CAG dependent manner. Reduced levels of lathosterol have
also been found in the brain of HdhQ111 K-IN mice com-
pared to WT HdhQ7/7 mice and in the brain of transgenic
HD rats with respect to control samples. The same data has
been obtained in brain from R6/2 mice. Other cholesterol pre-
cursors, cholesterol itself and the brain-specific catabolite 24-
hydroxycholesterol (24OHC) decrease similarly in all HD sam-
ples tested which included R6/2, YAC and KIN mice and HD
transgenic rats. Preliminary results also suggest that choles-
terol biosynthesis is specifically reduced in primary astrocytes
from YAC128 mice with respect to control cells. Notably,
primary astrocytes from YAC18 mice, over-expressing normal
huntingtin, show increased mRNA levels of key-cholesterol
biosynthesis genes compared to wt and more if compared to
mutant cells.
Conclusions: Overall these data highlight that cholesterol bio-
synthesis is reduced in the adult brain of different HD animal
models and that glial cells may be the source of such a defect.
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Background: A pathological hallmark of Huntington’s disease
(HD) is the aggregation of misfolded mutant huntingtin
(mHtt) in inclusion bodies in the nucleus and cytosol of neu-
rons. Molecular chaperones, especially members of the Hsp70
and Hsp40 families, co-localize to inclusion bodies and are
neuroprotective in animal models of HD. Precisely how molec-
ular chaperones suppress mHtt toxicity in vivo is unclear, but
it may be due to direct effects of the chaperones on mHtt mis-
folding and aggregation.
Methods and Results: To analyze the effect of molecular chap-
erones on mHtt misfolding and aggregation, we used size-
exclusion chromatography and atomic force microscopy
(AFM). We show that mHtt fragments assemble into soluble
oligomeric species with a broad distribution of sizes and mor-
phologies. A subset of soluble oligomers reacts with the con-
formation-specific antibody A11, which previously had been
shown to detect oligomers but not monomers or fibrillar
aggregates formed by a polyglutamine peptide. This subset of
oligomers had a globular structure as shown by AFM analysis.
We found that Hsp70 and its co-factor Hsp40 co-fractionate
with soluble mHtt oligomers and inhibit formation of A11-
reactive oligomers in an ATP-dependent manner. Moreover,
overexpression of Hsp70 and Hsp40 in a PC12 cell model sup-
pressed formation of mHtt oligomers that react with A11.
Conclusion: These findings indicate that, in addition to recog-
nizing mHtt monomers, Hsp70 and Hsp40 also interact with
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